Wizita Healthcare stopped accepting fresh customer orders effective 14th June 2021. Wizita is a Point-of-Care Diagnostics startup that employs cutting edge non-invasive POC technology with algorithm-based reporting or AI-powered reporting to diagnose vital body parts – which are generally not screened (unless it’s too late) – Feet, Peripheries, Lungs, Bones, Body Composition, Eyes. The core objective is to prevent what is preventable. Wizita targets specific health conditions that are highly preventable, or the scope of impacting health outcomes are very high like Diabetes, Hypertension, High Cholesterol, Obesity, Retinopathy, Neuropathy, Peripheral Artery Disorders, and other non-communicable conditions. Our purpose is to enhance existing capabilities present in Healthcare ecosystem and create new capabilities to positively impact the Consumer & Medical Practitioner. We respect Financial Capital and already built Service Capabilities. Our focus is to optimize both - the Capital and Capacity invested in Healthcare Ecosystem. Wizita wants to be to become the ever-reliable friend for the healthcare ecosystem and the healthcare consumer. Create capability and enhance the existing capability to do what we aspire to do – help and serve. Our goal is to win the friendship of the healthcare ecosystem and foster a culture of service. The Diabetic Neuropathy business of Wizita Healthcare moved to the pioneering health-tech OEM Yostra Labs Pvt Ltd - www.yostra.com The Health Risk Assessment business of Wizita Healthcare moved to Biogenick Life (Ecura Labs Pvt Ltd) - www.biogenick.com Wizita stopped taking fresh customer orders effective 14th June 2021.